News

DoD Delays Transgender Ban Pending New Study

Defense Secretary Jim Mattis has called for a new study of the impact of transgender troops on the military that will focus on readiness, cohesion, and costs.


 

Following the directive of the “ Military Service by Transgender Individuals ” Presidential Memorandum to reinstitute a ban on service for transgender service members, the Secretary of Defense has called for a new study of the impact of transgender service members on “military readiness, lethality, and unit cohesion, with due regard for budgetary constraints and consistent with applicable law.” Secretary of Defense Jim Mattis announced that he will “establish a panel of experts serving within the Departments of Defense and Homeland Security to provide advice and recommendations on the implementation of the president’s direction.”

The study follows on the heels of a July 2016 study issued by the RAND Corporation, which found that there are between 1,300 to 6,600 transgender active duty service members. According to the study, the “costs of gender transition-related health care are relatively low” and they had a “minimal” impact on force readiness.

The new study is due to President Trump by February 21, 2018 and is required to include a plan for implementing the ban. The potential ban on transgender service members is still set to go into effect March 23, 2018. However, there is some disagreement over whether the Presidential Memorandum leave the DoD with latitude to protect currently serving transgender service members or not.

The expected health care costs associated with transgender service members remains a significant factor in the policy decision. The RAND study estimated that health care costs would increase by between $2.4 million and $8.4 million annually with transgender service members out of an estimated $6.2 billion spent on active component health care spending, which would represent a 0.04% to 0.13% of the budget.

Recommended Reading

Protective Foam Gives Wounded a ‘Fighting Chance for Survival’
Federal Practitioner
VA Health Equity Report Details Disparities in Care
Federal Practitioner
Latest in Ongoing IHS Effort Against Opioid Epidemic
Federal Practitioner
What’s in a Name? AIDS.gov Becomes HIV.gov
Federal Practitioner
Rare Case of Orbital Involvement from Multiple Myeloma
Federal Practitioner
The Effect of Time on Arterial Pressure
Federal Practitioner
A Patient With Diabetes, Renal Disease, and Melanoma
Federal Practitioner
New NIH-Supported HIV Vaccine Efficacy Study Begins
Federal Practitioner
DoD, VA Join Federal Response to Harvey
Federal Practitioner
FDA approves first gene therapy – tisagenlecleucel for ALL
Federal Practitioner

Related Articles